Department of Pharmacology & Toxicology, Faculty of Pharmacy, Mansoura University, 35516 Mansoura, Egypt.
Department of Pharmacology & Toxicology, Faculty of Pharmacy, Mansoura University, 35516 Mansoura, Egypt.
Life Sci. 2020 Feb 15;243:117275. doi: 10.1016/j.lfs.2020.117275. Epub 2020 Jan 8.
Imatinib is an effective tyrosine kinase inhibitor which has different therapeutic actions. The recent work demonstrated the possible beneficial effects of imatinib on the progression of atherosclerosis, endothelial dysfunction, and hypercholesterolemia-associated liver damage in rabbits.
Animals had been distributed in 4 groups: group 1 (non-treated): animals fed regular diet; group 2 high cholesterol [HC]: animals fed 1% cholesterol supplemented diet for 30 days; group 3 (HC-Imatinib): animals fed 1% cholesterol supplemented diet+imatinib (0.01 g/kg daily, p.o) for 30 days; group 4 (Imatinib): animals fed regular diet with imatinib (0.01 g/kg daily, p.o). After thirty days, tissue samples and blood were isolated to be detected biochemically, histologically, and for in vitro analysis.
HC exhibited significant elevations in serum lipid parameters, CRP, ALT, AST and ALP. Additionally, HC induced significant increases for aortic and hepatic MDA, aortic NO and hepatic PDGFR-β, while significantly exhibited reductions in aortic and hepatic GSH, SOD and hepatic PPARγ1. Moreover, HC produced impairment in ACh-enhanced aortic relaxation and aortic pathological changes. Histopathological examination of HC-fed rabbits revealed hepatic steatosis compared with non-treated group. Imatinib administration exhibited significant decreases in serum lipid parameters, CRP, ALT, AST and ALP. Additionally, imatinib induced significant decreases for aortic and hepatic MDA, aortic NO and hepatic PDGFR-β, while significantly exhibited elevations in aortic and hepatic GSH, SOD and hepatic PPARγ1 compared with HC animals. Furthermore, imatinib significantly protected against HC produced attenuation in ACh-induced aortic relaxation and pathological changes in aortic and hepatic tissues. Interestingly, imatinib could return serum CRP, ALP, hepatic SOD and PDGFR-β to basal values.
The recent observation reports that imatinib could have beneficial effect against atherosclerosis progression, vascular malfunction, and liver damage in high cholesterol diet (HCD)-fed rabbits.
伊马替尼是一种有效的酪氨酸激酶抑制剂,具有不同的治疗作用。最近的研究表明,伊马替尼可能对兔动脉粥样硬化、内皮功能障碍和高胆固醇血症相关肝损伤的进展具有有益作用。
动物被分为 4 组:第 1 组(未治疗):给予常规饮食的动物;第 2 组高胆固醇(HC):给予 1%胆固醇补充饮食 30 天的动物;第 3 组(HC-伊马替尼):给予 1%胆固醇补充饮食+伊马替尼(0.01 g/kg,每日口服)30 天的动物;第 4 组(伊马替尼):给予常规饮食+伊马替尼(0.01 g/kg,每日口服)的动物。30 天后,分离组织样本和血液进行生化、组织学和体外分析。
HC 显著升高血清脂质参数、CRP、ALT、AST 和 ALP。此外,HC 诱导主动脉和肝 MDA、主动脉 NO 和肝 PDGFR-β显著增加,而主动脉和肝 GSH、SOD 和肝 PPARγ1 显著减少。此外,HC 导致 ACh 增强的主动脉松弛受损和主动脉病理变化。与未治疗组相比,HC 喂养的兔肝组织学检查显示肝脂肪变性。伊马替尼给药显著降低血清脂质参数、CRP、ALT、AST 和 ALP。此外,伊马替尼诱导主动脉和肝 MDA、主动脉 NO 和肝 PDGFR-β显著降低,而主动脉和肝 GSH、SOD 和肝 PPARγ1 显著升高与 HC 动物相比。此外,伊马替尼显著保护 HC 引起的 ACh 诱导的主动脉松弛和主动脉和肝组织的病理变化。有趣的是,伊马替尼可以使血清 CRP、ALP、肝 SOD 和 PDGFR-β恢复到基础值。
最近的观察报告表明,伊马替尼可能对高胆固醇饮食(HCD)喂养的兔动脉粥样硬化进展、血管功能障碍和肝损伤具有有益作用。